528 related articles for article (PubMed ID: 7723794)
21. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
22. The androgen receptor gene and its influence on the development and progression of prostate cancer.
Montgomery JS; Price DK; Figg WD
J Pathol; 2001 Sep; 195(2):138-46. PubMed ID: 11592091
[TBL] [Abstract][Full Text] [Related]
23. Androgen-regulated gene expression in prostate cancer.
Trapman J; Cleutjens KB
Semin Cancer Biol; 1997 Feb; 8(1):29-36. PubMed ID: 9299579
[TBL] [Abstract][Full Text] [Related]
24. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor gene mutations in hormone-refractory prostate cancer.
Wallén MJ; Linja M; Kaartinen K; Schleutker J; Visakorpi T
J Pathol; 1999 Dec; 189(4):559-63. PubMed ID: 10629558
[TBL] [Abstract][Full Text] [Related]
26. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression.
Shariat SF; Lamb DJ; Iyengar RG; Roehrborn CG; Slawin KM
Clin Cancer Res; 2008 Jan; 14(2):607-11. PubMed ID: 18223237
[TBL] [Abstract][Full Text] [Related]
27. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
28. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
29. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
30. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
31. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
32. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
33. Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha).
Anastasiadis AG; Ghafar MA; Salomon L; Vacherot F; Benedit P; Chen MW; Shabsigh A; Burchardt M; Chopin DK; Shabsigh R; Buttyan R
J Cancer Res Clin Oncol; 2002 Jul; 128(7):358-62. PubMed ID: 12136249
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
35. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ;
J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
[TBL] [Abstract][Full Text] [Related]
38. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
Qi H; Fillion C; Labrie Y; Grenier J; Fournier A; Berger L; El-Alfy M; Labrie C
Cancer Res; 2002 Feb; 62(3):721-33. PubMed ID: 11830526
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
[TBL] [Abstract][Full Text] [Related]
40. Amplification and co-regulators of androgen receptor gene in prostate cancer.
Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
